Investors who lost money on Skye Bioscience, Inc.(SKYE) should contact The Gross Law Firm about pending Class Action - SKYE

Core Viewpoint - The Gross Law Firm is notifying shareholders of Skye Bioscience, Inc. regarding a class action lawsuit due to alleged misleading statements about the company's lead product candidate, nimacimab [1][3]. Group 1: Allegations - The complaint alleges that during the class period from November 4, 2024, to October 3, 2025, the defendants issued materially false and misleading statements regarding nimacimab's effectiveness [3]. - It is claimed that the clinical, regulatory, and commercial prospects of nimacimab were overstated, leading to inflated public statements by the defendants [3]. Group 2: Shareholder Actions - Shareholders who purchased shares of SKYE during the specified class period are encouraged to register for the class action, with a deadline set for January 16, 2026 [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the status of the case [4]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect the rights of investors who have suffered due to deceit and illegal business practices, emphasizing the importance of responsible corporate behavior [5].